此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

颈动脉支架置入术中肱动脉与股动脉的比较 (BEFIT)

2026年9月22日 更新者:Liu Sheng、The First Affiliated Hospital with Nanjing Medical University

肱动脉与股动脉介入颈动脉支架置入术:多中心随机临床试验 (BEFIT)

Study purpose:

A multicenter, prospective and randomized study is planned to compare the clinical outcomes of carotid artery stenting via brachial artery access and femoral artery access.

Eligible participants will be randomly assigned 1:1 to the brachial artery group or the femoral artery group.

Primary endpoint: surgical success rate.

Secondary endpoints:

  1. Operation time (time from first arterial puncture to last angiography)
  2. Serious adverse events (SAE) within 90 days;
  3. Access puncture complications;

研究概览

详细说明

With the improvement of treatment concepts and the continuous innovation of interventional devices/interventional technologies, neurointervention has become the preferred treatment method for many cerebrovascular diseases. Among them, the femoral artery is the most commonly used access, because the femoral artery is superficial, easy to touch, and the relatively large vessel diameter allows most neurointerventional surgeries to proceed smoothly. However, the femoral artery access also has the disadvantages of long bed rest time, exposure to private parts, and prolonged hospitalization.

Thanks to the great success of radial artery access in cardiac intervention, radial artery access is increasingly being used in neurointervention. However, due to the thin radial artery, there is a significantly increased risk of complications (radial artery spasm, radial artery occlusion) during large-cavity nerve intervention, and the operation time is significantly prolonged. Therefore, the overall proportion of neurointerventional treatment via radial artery access in clinical practice is less than 12%.

As the superior vascular trunk of the radial artery, the brachial artery has a larger diameter and is theoretically more suitable to replace the radial artery for large-bore intervention. Anatomically, the brachial artery is superficial and easy to touch in the antecubital fossa, and there are no important vessels and nerves in front of the blood vessel, and the posterior is the distal humeral platform, which is easy for brachial artery puncture and postoperative compression hemostasis. Studies have shown that thrombectomy for cerebral artery occlusion and carotid artery stent placement can be safely performed through the brachial artery. However, current studies are based on single-center small sample studies, and there is still a lack of large-sample randomized controlled trials to verify the safety and effectiveness of neurointervention via the brachial artery.

This study intends to conduct a multicenter, prospective, and randomized study to compare the clinical results of carotid artery stent placement via the brachial and femoral artery access.

研究类型

介入性

注册 (实际的)

235

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Jiangsu
      • Nanjing、Jiangsu、中国、210000
        • The First Affiliated Hospital of Nanjing Medical University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Clinical diagnosis of stenosis at the origin of the carotid artery with indications for neuro-interventional treatment (symptomatic stenosis >50%; asymptomatic stenosis >70%)
  • Aged 18 or above
  • With palpable brachial and femoral arteries
  • The patient or his/her agent understands the purpose and needs of this study and signs the informed consent

Exclusion Criteria:

  • Symptomatic stenosis or occlusion of multiple vessels at the same time
  • Intravascular intervention for multiple vessel lesions at the same time
  • Ischemic stroke within the past 2 weeks
  • Any active bleeding, severe anaemia, or coagulation disorder. At least one of the following laboratory tests must be met: haemoglobin < 10g/dL, or platelet count < 100,000 /μ L, or unadjusted INR >1.5, or PT exceeds the upper limit of normal by 1 minute or heparin-induced thrombocytopenia
  • A large-area cerebral infarction stroke on the same side with sequelae may affect the judgment of the study endpoint
  • A history of cerebral hemorrhage in the past six months
  • Any condition that may interfere with digital subtraction angiography (DSA) or cause unsafe percutaneous arterial access Participating in other clinical trials, in the research stage or follow-up stage
  • Contraindications to cerebral angiography, such as allergy to iodine contrast agents and renal insufficiency
  • Unable to understand or sign the informed consent form
  • Severe functional damage to important organs, assessed by clinical physicians to have high surgical risks and intolerant of interventional surgery
  • Baseline modified Rankin scale greater than or equal to 2
  • Expected survival is less than 6 months

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:the brachial group

Patients with carotid artery stenosis will be randomly selected for carotid artery stenting via the brachial artery access.

CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.

有源比较器:the femoral group

Patients with carotid artery stenosis will be randomly selected for carotid artery stenting via the femoral artery access.

CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Successful rate of CAS
大体时间:24 hours

Successful carotid artery stenting (CAS) is defined as access devices can be established, interventional devices can reach the lesion site, operations such as distal brain protection device release, balloon expansion and stent implantation, withdrawal protection device can be completed successfully, and residual stenosis < 30%.

24 hours

次要结果测量

结果测量
措施说明
大体时间
Procedure time
大体时间:24 hours

time from first arterial puncture to last angiography

24 hours
Serious adverse events (SAE)
大体时间:90 days

SAEs related to operation and device are defined as those related to operation procedure and device determined by investigators. Includes the incidence of death, new-onset stroke, or severe haemorrhage events within 90 days post-procedure, et al.

90 days
Access puncture complications
大体时间:90 days

Hematoma at access puncture site, pseudoaneurysm, arteriovenous fistula, symptomatic severe stenosis/occlusion

90 days

其他结果措施

结果测量
措施说明
大体时间
X-ray exposure
大体时间:24 hours

X-ray exposure is defined as the duration and equivalent of X-ray exposure recorded by the DSA machine during operation.

24 hours
Access conversion
大体时间:24 hours

If the randomized access was not successfully completed, switched to other access

24 hours
Degree of patient-reported comfort
大体时间:24 hours

The comfort scale adopts the simplified General Comfort Questionnaire (GCQ)developed by nursing expert Kolcaba. The scale is scored by level 1 to 4 Likert scale, with a score range of 28-112 points. The lowest score is 28 points and the highest score is 112 points. The higher the score, the higher the comfort. A total score of < 60 is low comfort, a total score of 60-90 is moderate comfort, and a total score of > 90 is high comfort.

24 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sheng Liu, Professor、The First Affiliated Hospital with Nanjing Medical University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月27日

初级完成 (实际的)

2026年8月31日

研究完成 (实际的)

2026年8月31日

研究注册日期

首次提交

2024年8月12日

首先提交符合 QC 标准的

2024年8月13日

首次发布 (实际的)

2024年8月16日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅